311 related articles for article (PubMed ID: 28735662)
21. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
22. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids.
Jindal T; Kumar A; Venkitaraman B; Meena M; Kumar R; Malhotra A; Dutta R
Cancer Imaging; 2011 Jun; 11(1):70-5. PubMed ID: 21697027
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
[TBL] [Abstract][Full Text] [Related]
25. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.
Kumar R; Sharma P; Garg P; Karunanithi S; Naswa N; Sharma R; Thulkar S; Lata S; Malhotra A
Eur Radiol; 2011 Nov; 21(11):2408-16. PubMed ID: 21750886
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the application of 18F-FDG and 68Ga-DOTATATE PET/CT in neuroendocrine tumors: A retrospective study.
Hu X; Li D; Wang R; Wang P; Cai J
Medicine (Baltimore); 2023 May; 102(19):e33726. PubMed ID: 37171344
[TBL] [Abstract][Full Text] [Related]
27. Neuroendocrine tumour of the mediastinum: fusion of 18F-FDG and 68Ga-DOTATOC PET/CT datasets demonstrates different degrees of differentiation.
von Falck C; Boerner AR; Galanski M; Knapp WH
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):812. PubMed ID: 17242919
[No Abstract] [Full Text] [Related]
28. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
29. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
30. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
31. Early Dynamic 68Ga-DOTA-D-Phe1-Tyr3-Octreotide PET/CT in Patients With Hepatic Metastases of Neuroendocrine Tumors.
Sänger PW; Freesmeyer M
Clin Nucl Med; 2016 Jun; 41(6):447-53. PubMed ID: 26859210
[TBL] [Abstract][Full Text] [Related]
32. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.
Buchmann I; Henze M; Engelbrecht S; Eisenhut M; Runz A; Schäfer M; Schilling T; Haufe S; Herrmann T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1617-26. PubMed ID: 17520251
[TBL] [Abstract][Full Text] [Related]
33. Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients. Correlation of parameters during PRRT.
Van Binnebeek S; Koole M; Terwinghe C; Baete K; Vanbilloen B; Haustermans K; Clement PM; Bogaerts K; Verbruggen A; Nackaerts K; Van Cutsem E; Verslype C; Mottaghy FM; Deroose CM
Nuklearmedizin; 2016 Jun; 55(3):104-14. PubMed ID: 27056060
[TBL] [Abstract][Full Text] [Related]
34. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
35. Combined 68Ga-DOTATOC and 18F-FDG PET Predicts a Double Component With Different Grade of a Pancreatic Neuroendocrine Tumor in a Patient With Multiple Endocrine Neoplasia Type 1.
Paepegaey AC; Gaujoux S; Meyer C; Rouquette A; Libé R
Clin Nucl Med; 2020 Jun; 45(6):e281-e282. PubMed ID: 32349092
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of
Sawicki LM; Deuschl C; Beiderwellen K; Ruhlmann V; Poeppel TD; Heusch P; Lahner H; Führer D; Bockisch A; Herrmann K; Forsting M; Antoch G; Umutlu L
Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
[TBL] [Abstract][Full Text] [Related]
38. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors.
Abdulrezzak U; Kurt YK; Kula M; Tutus A
Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719
[TBL] [Abstract][Full Text] [Related]
39. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.
Schreiter NF; Brenner W; Nogami M; Buchert R; Huppertz A; Pape UF; Prasad V; Hamm B; Maurer MH
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):72-82. PubMed ID: 21927931
[TBL] [Abstract][Full Text] [Related]
40. Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT "Superscan" in Metastatic Pancreatic Neuroendocrine Tumor.
Chan M; Schembri GP
Clin Nucl Med; 2017 Feb; 42(2):108-109. PubMed ID: 27997429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
